ReNew Energy Global Plc files its Annual Report on Form 20-F for Financial Year ended March 31, 2025
About ReNew:
ReNew is a leading decarbonization solutions company listed on Nasdaq (Nasdaq: RNW, RNWWW). ReNew's clean energy portfolio of ~18.5 GWs on a gross basis as of June 16, 2025, is one of the largest globally. In addition to being a major independent power producer in India, we provide end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. For more information, visit renew.com and follow us on LinkedIn, Facebook, Twitter and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
41 minutes ago
- CTV News
Canada in ‘no man's land' as new U.S. tariffs take effect, former foreign minister warns
Prime Minister Mark Carney listens as U.S. President Donald Trump speaks during a group photo at the G7 Summit, Monday, June 16, 2025, in Kananaskis, Canada. (AP Photo/Mark Schiefelbein) Canada is bracing for further tension in its trade relationship with the United States, after President Donald Trump imposed sweeping new tariffs. 'This is bad news,' said former foreign affairs minister Peter MacKay in an interview with CTV News Channel Sunday. 'It's bad news for the markets. It's bad news for many sectors on both sides of the border. … There is a lot of impetus now to try to bring this to an end.' Trump hit Canadian goods with a 35-per-cent tariff on Friday—targeting products not compliant with the Canada-U.S.-Mexico Agreement. The White House said the decision was made in response to Canada's 'failure to co-operate' on stemming fentanyl imports and Ottawa's retaliatory duties. Trump also introduced 50-per-cent tariffs on semi-finished copper products and maintained existing duties on Canadian steel, aluminum and automobiles. Dominic LeBlanc, Canada's trade minister, said Sunday he expects Prime Minister Mark Carney and Trump to speak 'over the next number of days' in a renewed effort to de-escalate the dispute. MacKay, meanwhile, says high-level talks are essential, especially given Trump's direct involvement. 'Having personal discussions with our prime minister … is probably the only way we are going to see this trade agreement finally get done,' he said. MacKay warned that while some 75 per cent of goods crossing the border remain tariff-free, critical sectors like steel, aluminum, copper and autos are facing sharp new costs. He also cautioned that the trade war risks turning personal. 'We've seen what happens, as recently as with the former Prime Minister Trudeau, when it does get personal,' he said. 'The Canadian economy ultimately and quickly pays a price.' Trump signed the executive order late Thursday. The Aug. 1 target date floated for a potential deal passed without progress, and there is still no clear timeline for resolution. MacKay described this current phase as 'no man's land.' 'We are not even where we used to be,' he said. 'Let's just hope that (Trump) doesn't go wildly off in all directions on the eve of getting to some sort of a finish line.' With files from the Canadian Press
Globe and Mail
an hour ago
- Globe and Mail
Prediction: This Quantum Computing Stock Will Be Worth More Than Berkshire Hathaway, Palantir, and Tesla Combined by 2030
Key Points Google parent Alphabet is already nearly worth more than Berkshire, Palantir, and Tesla combined. If a few key assumptions hold up, the stock should be larger than these three companies within the near future. Quantum computing probably won't be Alphabet's biggest growth driver, though. 10 stocks we like better than Alphabet › What do Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), Palantir Technologies (NASDAQ: PLTR), and Tesla (NASDAQ: TSLA) have in common? Not much. However, they're all large-cap companies that have achieved significant success in recent years. There's one common denominator we can definitely cross of the list: None of these three companies has quantum computing developments underway. But another tech giant does. And I predict it will be worth more than Berkshire, Palantir, and Tesla combined by 2030. A potential quantum computing monster The potential quantum computing monster I have in mind is Google parent Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL). My prediction doesn't require stepping out on a limb too much. Alphabet's market cap currently hovers around $2.3 trillion. That's only a little below the $2.4 trillion combined market caps of Berkshire Hathaway ($1.04 trillion), Palantir ($374 billion), and Tesla ($966 million). All Alphabet needs to do is grow a little faster than these three stocks over the next five years. I think that's doable. However, a few things have to happen for my prediction to pan out that have nothing to do with Alphabet. All bets are off if Berkshire Hathaway pulls off a massive acquisition under Warren Buffett's successor, Greg Abel, that turbocharges the company's growth. My hunch, though, is that Abel won't attempt anything fraught with such risk in his first few years as CEO. I'm assuming that Palantir's valuation catches up with it or that its growth doesn't catch up with its valuation. With the stock trading at a forward price-to-earnings ratio of nearly 278 and growth that doesn't come close to justifying this premium, I suspect I'm on pretty safe ground. With Tesla, I'm anticipating intense competition in the electric vehicle market from BYD and others. I'm banking on Cathie Wood and her Ark Invest team being wrong about projections that Tesla's market cap will skyrocket as the robotaxi market takes off. I'm also counting on it taking more than five years for Tesla to have a major commercial hit with its Optimus humanoid robots. Quantum computing and more Of course, Alphabet must deliver strong growth even if my assumptions about Berkshire, Palantir, and Tesla hold up. I'm optimistic that it will. By the way, my prediction doesn't hinge on the company having a major quantum computing breakthrough. That is a distinct possibility, though. Google Quantum AI has already achieved two of the six milestones on its quantum computing roadmap. It believes that building a useful quantum computer is feasible within this decade, too. What I am counting on is continued impressive growth from Google Cloud. The unit's revenue soared 32% year over year in the second quarter of 2025, the fastest growth rate among the big three cloud service providers. With a massive artificial intelligence (AI) tailwind at its back, I think sustained momentum for Google Cloud should be a pretty safe bet. I also look for Google Search, YouTube, and Alphabet's other advertising moneymakers to remain dominant in their markets. Some have warned of an existential threat to Google Search from generative AI. All I've seen so far is Google's generative AI initiatives helping secure its position in the search engine market. While I assume that the robotaxi market won't be big enough to give Tesla a market cap of nearly $10 trillion by 2030, I do think it could provide a nice boost to Alphabet's Waymo unit. The self-driving car business is likely to become an increasingly important growth driver for Alphabet. The elephant in the article Admittedly, there is a potential fly in the ointment with my prediction. It's also the elephant in the room (or, in this case, the article). Could the antitrust actions against Google threaten Alphabet's growth? Probably the best answer to this question is... maybe. However, I don't think it will happen before 2030. Google is appealing the two federal court rulings that went against it. The legal process could drag out for years. I wouldn't bet against the company prevailing. Even if it doesn't, my hunch is that most of the factors that currently make the stock attractive would remain intact. We'll know in five years if my prediction comes true. In the meantime, I view Alphabet as the best quantum computing stock (and one of the best AI stocks) on the market. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
National Post
2 hours ago
- National Post
Nucleus Network Acquires Hammersmith Medicines Research
Article content BRISBANE, Australia & LONDON — Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom's most respected early phase clinical trial organisations. This milestone marks a significant step in Nucleus Network's global growth, establishing the only early phase provider with dedicated facilities in Australia, the United States, and the United Kingdom. Article content The acquisition brings together two organisations with a shared mission: advancing medicine and improving lives. It also honours the legacy of Dr Malcolm Boyce, whose leadership established HMR as a centre of excellence in early phase research across the UK and Europe. With complementary scientific expertise and a strong, mutual commitment to participant safety and ethical conduct, the combined organisation is well positioned to accelerate clinical development and deliver inclusive, high-quality studies across three continents. Article content 'We are deeply honoured by the trust Dr Boyce has placed in us to carry forward HMR's legacy,' said Article content . 'This acquisition is about more than expanding our global footprint. It reflects a genuine alignment of values, culture, and purpose. Together, we are building a platform that will help redefine the way early phase trials are delivered.' Article content A New Standard for Early-Phase Clinical Trials Article content With the acquisition of HMR, Nucleus Network is setting a new global benchmark in the delivery of early-phase clinical trials. Sponsors now benefit from a fully integrated model that combines global reach with deep local expertise. By harnessing the strength of our globally leading and multi-jurisdictional business development team, we will work in close partnership with sponsors to guide trials to the geographic locations that best align with their strategic priorities. Studies can commence in one regulatory environment and seamlessly transition to another, enabled by harmonised processes and consistently high-quality standards, accelerating timelines and reducing operational risk. Article content The expanded geographic footprint expands access to broader and more diverse volunteer and patient populations. This scale supports faster recruitment and more inclusive study designs, both of which are critical for first-in-human and adaptive trial protocols. HMR's decades of scientific and operational excellence complement Nucleus Network's advanced infrastructure and digital capabilities. Together, they bring added precision to study execution and data quality, driving robust outcomes across all sites. Article content Sponsors will experience more streamlined engagement through unified systems, shared best practices, and coordinated project delivery, simplifying the complexities of early-phase trial execution. This integration further strengthens Nucleus Network's position as the most experienced global provider dedicated to early-phase clinical research. Article content At the same time, Nucleus Network will continue to partner with CROs around the world, offering flexible services that complement existing partnerships and extend reach across geographies. Article content ' This acquisition expands what's possible for our sponsors,' Pisarev added. 'It deepens our scientific capabilities, strengthens our operational reach, and reinforces our commitment to delivering life-changing therapies to patients around the world.' Nucleus Network will continue to operate its clinical sites in Brisbane, Melbourne, and Sydney (from ~2026), Australia; Minneapolis, Minnesota; and London, England, ensuring continuity for ongoing studies and trusted relationships. Article content Nucleus Network is the only early-phase clinical research provider with a global footprint, operating dedicated Phase I facilities in Australia, the United States, and the United Kingdom. With over 20 years of experience and more than 1,500 first-in-human studies conducted, Nucleus Network is recognized for its scientific excellence, operational integrity, and commitment to innovation. Article content Article content Article content Article content Contacts Article content Media Contact Article content
